PlexusDx providers can review your medical history and current symptoms to advise whether ACV is appropriate for your individual case
Weight loss alone can reduce apnea hypopnea events and nighttime oxygen drops. Tirzepatide (Zepbound) is now FDAapproved specifically to treat OSA in adults with obesity, backed by SURMOUNTOSA trials showing large drops in apneahypopnea index, hypoxic burden, and body weight versus placebo. Semaglutide is not OSAapproved but still improves apnea severity in some patients as weight and visceral fat come down, with emerging data suggesting symptom relief and better functional scores. For sleep apnea driven by obesity, both agents can help, but tirzepatide is the one positioned as a direct OSA drug today
Before FDA approval, analysts at Leerink Partners forecast orforglipron pricing 10% to 15% below Zepbound, in the $935 to $990 monthly range
Microdosing acts as an initial strategy focused on comfort, but it is not meant to replace correct therapeutic doses
That's a total of 2.4mL that's used This means there's 0.6mL remaining as an overfill which is part of the Kwiken's current design
Beyond 16 weeks: Reassessment
